Shares of Acadia Healthcare Company Inc (NASDAQ:ACHC) have been assigned an average rating of “Buy” from the eighteen analysts that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $45.67.
A number of equities research analysts recently commented on ACHC shares. Royal Bank of Canada restated a “buy” rating and set a $45.00 price objective on shares of Acadia Healthcare in a report on Tuesday, February 27th. BidaskClub upgraded shares of Acadia Healthcare from a “hold” rating to a “buy” rating in a report on Thursday, February 22nd. Jefferies Group set a $42.00 price objective on shares of Acadia Healthcare and gave the stock a “buy” rating in a report on Tuesday, December 19th. Robert W. Baird set a $42.00 price objective on shares of Acadia Healthcare and gave the stock a “hold” rating in a report on Thursday, February 22nd. Finally, Zacks Investment Research upgraded shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a report on Monday, February 12th.
In related news, Director Reeve B. Waud sold 7,698 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $42.03, for a total value of $323,546.94. Following the completion of the transaction, the director now owns 10,088 shares of the company’s stock, valued at $423,998.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Randall P. Goldberg sold 960 shares of the firm’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $38.47, for a total transaction of $36,931.20. Following the completion of the transaction, the vice president now directly owns 6,942 shares of the company’s stock, valued at approximately $267,058.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 400,960 shares of company stock valued at $15,742,508. 11.10% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors grew its position in shares of Acadia Healthcare by 5.2% in the 3rd quarter. Nationwide Fund Advisors now owns 259,773 shares of the company’s stock valued at $12,407,000 after acquiring an additional 12,931 shares during the period. Neuberger Berman Group LLC grew its position in shares of Acadia Healthcare by 5.1% in the 3rd quarter. Neuberger Berman Group LLC now owns 879,951 shares of the company’s stock valued at $42,026,000 after acquiring an additional 42,713 shares during the period. GW&K Investment Management LLC grew its position in shares of Acadia Healthcare by 3.6% in the 4th quarter. GW&K Investment Management LLC now owns 454,684 shares of the company’s stock valued at $14,836,000 after acquiring an additional 15,801 shares during the period. Jennison Associates LLC grew its position in shares of Acadia Healthcare by 6.5% in the 4th quarter. Jennison Associates LLC now owns 859,360 shares of the company’s stock valued at $28,041,000 after acquiring an additional 52,473 shares during the period. Finally, FDx Advisors Inc. bought a new position in shares of Acadia Healthcare in the 3rd quarter valued at about $779,000.
Shares of Acadia Healthcare (NASDAQ ACHC) traded down $0.55 during trading hours on Friday, hitting $41.16. 1,310,514 shares of the company were exchanged, compared to its average volume of 1,257,323. Acadia Healthcare has a fifty-two week low of $26.92 and a fifty-two week high of $54.34. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.25. The firm has a market capitalization of $3,657.84, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 1.36 and a beta of 0.69.
Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.07. Acadia Healthcare had a net margin of 6.92% and a return on equity of 8.16%. The business had revenue of $724.50 million for the quarter, compared to analyst estimates of $713.20 million. During the same period last year, the business posted $0.59 earnings per share. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. equities analysts predict that Acadia Healthcare will post 2.45 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/brokerages-set-acadia-healthcare-company-inc-achc-price-target-at-45-67.html.
About Acadia Healthcare
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.